PRESS RELEASE 2020

Parsippany, NJ – December 18, 2020 – Beginning January 1, 2021, Ferring Pharmaceuticals will gain preferred access through CVS Health and Aetna formularies for EUFLEXXA® (1% sodium hyaluronate) for the treatment of knee osteoarthritis (OA) pain and exclusive preferred access on three out of four ...

CDC defines Clostridioides difficile (C. diff) infection as a significant healthcare burden to patients and physicians, labeling C. diff as a public health threat causing an estimated half a million illnesses and thousands of deaths annually in the US alone1,2,3 This is the first year that Ferrin...

Ferring and Rebiotix, a Ferring Company, will present two oral abstracts describing translational studies of investigational microbiome-based therapeutics RBX2660 and RBX7455 for the treatment of recurrent Clostridioides difficile(C. diff) infection These data presentations strengthen the company...

Ferring will deliver 11 presentations at the virtual congress; including six oral presentations The new data being presented further underscores Ferring’s commitment to supporting personalized fertility options to help people build families worldwide Parsippany, NJ – October 15, 2020 – Ferring Ph...

FOR IMMEDIATE RELEASE – Parsippany, NJ – August 5, 2020– Ferring Pharmaceuticals US is voluntarily recalling all lots on the market of DDAVP® Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE® Nasal Spray 1.5 mg/mL listed in the table below to the consumer...

ORTIKOS is available in one convenient pill in two dosage strengths (9mg, 6mg) for the treatment of mild to moderate active Crohn’s disease in patients 8 years and older and maintenance of clinical remission for up to three months in adults1 Approximately 800,000 Americans are currently living wi...

Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn’s disease in the U.S. Co-promotion strengthens commitment to patients living with Crohn’s disease by reaching more gastroenterologists while also continuing patient support programs Ferring is expanding its focus in specialty ar...

Ragans is now responsible for Ferring US commercial, manufacturing and development operations Ragans joined Ferring, a world leader in reproductive medicine, in 2012 and was named US Chief Commercial Officer in 2016 Parsippany, NJ – June 1, 2020 – Ferring Pharmaceuticals (US) announced today that...

MEGASET-HR (high responder) study met its primary non-inferiority endpoint, with Menopur-treated patients experiencing a 35.5% ongoing pregnancy rate (OPR) per cycle start after a fresh transfer, compared to 30.7% for rFSH-treated patients Evaluation of secondary and post-trial endpoints revealed...

Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial for RBX2660 RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridioides difficile (C. diff) infectio...

Fertility House Calls service offered to residents of Greater Denver metro area as part of a pilot program Personalized service designed to reduce the emotional burden associated with the fertility journey At-home fertility consultations can be set up online through a user-friendly platform Parsi...